Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 15/20 | 0.70 |
| ▸ | DRD2 | P14416 | 15/20 | 0.70 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.70 |
| ▸ | DRD4 | P21917 | 8/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046470 | 0.94 | DRD2 (0.69) | DRD3DRD2TMEM97DRD4CA2 | |
| SCHEMBL3046385 | 0.93 | DRD3 (0.62) | DRD3DRD2TMEM97DRD4CA2 | |
| SCHEMBL3049241 | 0.89 | DRD3 (0.71) | DRD3DRD2TMEM97DRD4CA2 | |
| SCHEMBL3506177 | 0.86 | CA2 (0.73) | DRD3DRD2TMEM97DRD4CA2 | |
| SCHEMBL3051392 | 0.86 | CA2 (0.73) | DRD3DRD2TMEM97DRD4CA2 | |
| SCHEMBL3061589 | 0.85 | KDM4E (0.63) | DRD3DRD2TMEM97DRD4CA2 | |
| SCHEMBL3048966 | 0.85 | CA9 (0.67) | DRD3DRD2TMEM97DRD4CA9 | |
| SCHEMBL3058965 | 0.85 | CA2 (0.67) | DRD3DRD2TMEM97DRD4CA2 | |
| SCHEMBL3051387 | 0.83 | KDM4E (0.69) | DRD3DRD2TMEM97DRD4CA2 | |
| SCHEMBL14703835 | 0.82 | CA2 (0.65) | DRD3DRD2TMEM97DRD4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | claimed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | DRD3 3408/4885DRD2 2317/4885TMEM97 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.